Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Monotherapy or Combination Therapy in Advanced NSCLC With Actionable Genomic Alterations
NCT07405190Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started May 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07405190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405190.